Science
Our R&D Pipeline
Research and development is the backbone of our healthcare innovation. Explore marketed specialty care and investigational programmes — with urology as a lead franchise.
| Programme | Area | Stage | Focus |
|---|---|---|---|
| Tamsulosin 0.4 mg | Urology | Marketed | BPH / urinary flow |
| Alfuzosin 10 mg ER | Urology | Marketed | Lower urinary-tract symptoms |
| Silodosin 8 mg | Urology | Marketed | BPH |
| Solifenacin 5 mg | Urology | Marketed | Overactive bladder |
| Investigational OAB antibody-device | Urology | Phase 2 | Unmet need in refractory OAB |
| Stone-prevention citrate programme | Urology | Phase 3 | Recurrent nephrolithiasis |
| Neuroscience movement-disorder asset | Neuroscience | Phase 2 | Partnered discovery |
| Immunology / IBD candidate | Immunology | Phase 1 | Early clinical |
| Biosimilar immunology mAb | Biosimilars | Development | Access programme |
Pipeline information is current as of publication and may change. Investigational programmes are not approved for the uses under study.